By Janice Tolj, MBA — Founder, Healthy Essentials After 50. Last updated September 1, 2026.
Affiliate disclosure: some links below are affiliate links. If you use one, I may earn a commission at no additional cost to you.
Yes, since July 1, 2026. The Medicare GLP-1 Bridge gives qualifying Part D members Wegovy, the Zepbound KwikPen, or Foundayo for a flat $50 a month through December 2027. Separately, Part D has covered Wegovy since 2024 when it is prescribed to reduce cardiovascular risk. Whether Medicare pays depends on why a drug is prescribed, not on which drug it is.
Medicare Covers the Reason, Not the Medication
This is the sentence that unlocks the whole subject, and it explains why two people can be prescribed the identical drug and only one of them pays almost nothing.
Ozempic and Wegovy contain the same active ingredient, semaglutide. Mounjaro and Zepbound are both tirzepatide. Medicare treats each pair completely differently, because Part D has always excluded drugs used for weight loss, a restriction it inherited from Medicaid rules written decades ago. Prescribed for type 2 diabetes, semaglutide is covered. Prescribed for weight loss, the same molecule was not.
That is the rule the last two years have been chipping away at, and as of this summer there is a genuine route to coverage that did not exist before. It is temporary, it sits outside the normal Part D benefit, and it has conditions. It is also the biggest change to Medicare drug access in years, and many people who qualify have not heard of it.
This is general education, not medical or insurance advice. These are serious prescription medications with real side effects, and every decision here belongs with your own doctor.
What This Looked Like for Me
I was denied. Not by Medicare, since at 63 I am not there yet, but by my own insurer, and for exactly the reason this article is about. I am obese, and my knees have reached the point where stairs are a decision rather than a reflex. But bad knees are not on any GLP-1 label. Osteoarthritis is not an approved indication, so there was no box to tick. The medication might have helped the thing that is actually wrong with me. That was never the question being asked.
I mention it because the same logic governs Medicare, and because a denial is not a judgment about whether you need something. It is a statement about whether your diagnosis appears on a label. Those are different things, and it is worth knowing which one you are arguing with.
The Medicare GLP-1 Bridge
The Bridge launched on July 1, 2026 and runs through December 31, 2027. It came out of a pricing agreement between the federal government and the manufacturers, and it is structured as a demonstration program rather than a permanent benefit, which matters for how it works.
What it covers
- Wegovy, in all formulations, including the injection and the daily tablet.
- The Zepbound KwikPen.
- Foundayo, in all formulations.
Ozempic and Mounjaro are not in the Bridge, because they are approved for diabetes rather than weight management. They remain covered under standard Part D when prescribed for type 2 diabetes. Compounded semaglutide and tirzepatide are excluded entirely; only FDA-approved brand-name products qualify.
Who qualifies
You must be enrolled in a participating Part D plan. Beyond that, eligibility rests on body weight and health status, with reported criteria covering a body mass index of 35 or higher, or 27 or higher combined with a related condition such as heart disease or prediabetes. Around 3.8 million beneficiaries are estimated to be eligible.
Your prescriber submits the request. If you already take one of these medications, your prescriber can attest that you met the clinical criteria when you started, so there is no need to stop and requalify.
The three things people get wrong
- The $50 copay sits outside your standard Part D benefit. It does not count toward your deductible, and it does not count toward the annual out-of-pocket cap, which is $2,100 in 2026. The upside of the same arrangement is that you also avoid specialty-tier coinsurance, which had been running several hundred dollars a month.
- You cannot use both routes for the same drug. If your plan already covers Wegovy for cardiovascular risk reduction, you cannot also take it through the Bridge.
- It ends on December 31, 2027. CMS has signalled a longer-term successor, sometimes referred to as the BALANCE Model, but that was delayed indefinitely in April 2026 and is not something to count on. Treat the Bridge as a window, not a permanent benefit.
The Route Most People Miss
Before the Bridge existed, one door was already open, and it is still the better option for some people.
In March 2024 the FDA approved Wegovy for reducing the risk of major cardiovascular events in adults with established heart disease who are overweight or obese. That is a cardiovascular indication, not a weight loss indication, so it falls outside the Part D exclusion. Following CMS guidance, Part D plans gained the ability to cover Wegovy for that purpose. The evidence behind it came from the SELECT trial, which found a roughly 20 percent reduction in major cardiovascular events.
Zepbound has a similar story from a different direction. It is FDA-approved for moderate to severe obstructive sleep apnea in adults with obesity, which is again a covered indication rather than weight loss, and a prescription written for sleep apnea is treated accordingly.
So the practical question to bring to your doctor is not “will Medicare pay for a weight loss drug.” It is “do I have a diagnosis that makes one of these medications appropriate on its own terms.” If you have established cardiovascular disease, or obstructive sleep apnea, or type 2 diabetes, the answer may already be yes, and coverage through your regular Part D benefit counts toward your out-of-pocket cap in a way the Bridge does not.
One line that has to be said plainly. Do not ask a doctor to write a diagnosis you do not have in order to obtain coverage. Medicare audits claims, and an inaccurate diagnosis code is fraud, with consequences for the prescriber as well as the patient.
Which Drug, Which Route
| Medication | Approved for | Medicare route | Notes |
| Wegovy | Weight management, cardiovascular risk, MASH | Bridge, or Part D for the CV indication | Injection and daily tablet; both in the Bridge |
| Zepbound | Weight management, obstructive sleep apnea | Bridge (KwikPen), or Part D for sleep apnea | Sleep apnea is the route with the longer runway |
| Foundayo | Weight management | Bridge, all formulations | Included from launch |
| Ozempic | Type 2 diabetes | Standard Part D | Not in the Bridge; same molecule as Wegovy |
| Mounjaro | Type 2 diabetes | Standard Part D | Not in the Bridge; same molecule as Zepbound |
| Compounded versions | Not FDA-approved | Not covered | Excluded from the Bridge and from Part D |
What It Costs, and What Changes in 2027
Through the Bridge, $50 a month for a 30-day supply, regardless of dose or formulation. That is the simplest pricing in the entire Medicare program right now.
Through standard Part D for a covered indication, you pay whatever your plan’s cost-sharing is for that tier, which historically meant specialty-tier coinsurance of several hundred dollars a month, though it does count toward the $2,100 annual cap.
Paying cash, list prices remain high, though manufacturer and government channels have brought real prices down substantially from where they were.
The date to watch is January 1, 2027. Semaglutide was selected for Medicare drug price negotiation, and CMS has set a negotiated price for a 30-day supply that is dramatically below the list price. Reporting on the November 2025 CMS fact sheet cites figures in the region of $274 a month, though published numbers vary, so confirm before relying on any specific amount. Whatever the final figure, the direction is clear, and 2027 will be considerably cheaper than 2026 for anyone covered through regular Part D.
That creates a genuine planning question for this autumn. If you start on the Bridge now, know that it ends in December 2027 and that what follows it is uncertain. During Open Enrollment, from October 15 to December 7, ask whether your Part D plan intends to participate in whatever succeeds the Bridge.
What This Means If You Are Over 65
Coverage is only half the decision, and the half that gets less attention deserves more.
Weight lost on these medications includes lean muscle as well as fat, and after 65 there is less margin for that. Age-related muscle loss is already underway, and an editorial in Annals of Internal Medicine has warned that GLP-1 medications may worsen sarcopenia in older patients. The consequences of losing muscle at this age are falls and fractures rather than a smaller dress size.
None of that is an argument against the medication. It is an argument for resistance training two or three times a week and adequate protein while you take it, and for choosing a prescriber who tracks something other than the number on the scale. Ask your doctor about both before you start, not after.
If You Do Not Qualify
- Ask about the indication first. Cardiovascular disease, sleep apnea, and type 2 diabetes each open a covered route that has nothing to do with the Bridge.
- Check your Advantage plan’s drug benefit. Advantage plans include Part D coverage and vary in what they cover and how they tier it.
- Look at manufacturer direct channels. Both manufacturers now sell directly at cash prices far below list, and those prices have been falling.
- Be careful with compounded versions. They are cheaper, they are not FDA-approved, they are not covered by anything, and the regulatory pathway allowing them is narrowing. If you go that route, understand what you are buying.
- Reconsider whether you need it. Not everyone carrying extra weight at 70 should be on a GLP-1. For some people the risks of losing muscle outweigh the benefit, and that is a real conversation to have with a doctor who knows your history.
Frequently Asked Questions
Does Medicare cover Wegovy in 2026?
Yes, by two routes. The GLP-1 Bridge covers all Wegovy formulations at $50 a month for qualifying Part D members through December 2027. Separately, Part D plans can cover Wegovy for cardiovascular risk reduction in people with established heart disease, following the FDA’s 2024 approval for that use.
Does Medicare cover Ozempic for weight loss?
No. Ozempic is approved for type 2 diabetes and is covered under Part D for that purpose. It is not in the Bridge. Wegovy contains the same active ingredient and is the product approved for weight management.
How do I apply for the GLP-1 Bridge?
You do not apply directly. Your prescriber submits the request on your behalf, and if you are already taking the medication your prescriber can attest that you met the criteria when you started. Talk to your doctor and confirm with your Part D plan that it is participating.
Does the $50 copay count toward my out-of-pocket cap?
No. The Bridge operates outside the standard Part D benefit, so the copays do not count toward your deductible or the $2,100 annual out-of-pocket maximum. The same structure is what protects you from specialty-tier coinsurance.
What happens when the Bridge ends in 2027?
That is unresolved. CMS has described a longer-term successor, but the model intended to follow it was delayed indefinitely in April 2026. Separately, negotiated pricing for semaglutide takes effect in Part D from January 2027, which should lower costs through the standard benefit. Ask about both during Open Enrollment.
Will Medicare cover compounded semaglutide?
No. Only FDA-approved brand-name products qualify, under the Bridge and under Part D. Compounded versions are a cash purchase with no insurance route.
Related Reading
Medicare Advantage Plans for Seniors ; What Medicare Covers and What it Does Not
The Short Version
If you have Medicare Part D and a BMI that meets the criteria, ask your prescriber about the GLP-1 Bridge at your next appointment. Fifty dollars a month for an FDA-approved medication, prescribed by a doctor who knows your history, is the best deal available anywhere in this category, and it exists for a limited time.
If you have heart disease, sleep apnea, or diabetes, ask about the indication route instead, since coverage through your regular Part D benefit counts toward your out-of-pocket cap and does not expire in December 2027.
And whichever door you go through, spend as much attention on protecting your muscle as you do on the coverage. The medication is the easy part.
About the Author
Janice Tolj, MBA, is the founder of Healthy Essentials After 50. She spent more than 30 years as a corporate Controller in financial compliance, including federal grant compliance at Johns Hopkins University, and served as her mother’s personal and financial guardian, managing her Medicare coverage and prescriptions. She is not a physician, a pharmacist, or a licensed insurance agent, and she is not affiliated with Medicare or any manufacturer named here.
Medical disclaimer: this article is general education, not medical advice. GLP-1 receptor agonists are prescription medications with serious potential side effects, including pancreatitis and gallbladder disease, and are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Consult a qualified healthcare provider before starting, stopping, or changing treatment.
Affiliate disclosure: this article contains affiliate links. If you use one, Healthy Essentials After 50 may earn a commission at no additional cost to you. Commissions never determine what is recommended.
Production Notes
REVIEW CADENCE: monthly, not annually. This is the fastest-moving topic on the site. The Bridge ends December 2027, negotiated pricing starts January 2027, and the compounding rules are still unresolved.
BACKLINKS IN: link from the GLP-1 provider article’s Medicare section, which currently explains the Bridge in summary.